FIC, oral, QD, cardiac myosin inhibitor FDA-approved for obstructive HCM opt. of HTS hit for sarcomere activity inhibition mavacamten (MYK461, CAMZYOS) Myokardia, Brisbane, CA; Bristol Myers Squibb, New York, NY